Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients

American Journal of Hematology

Volumn 88, Issue 7, 2013, Pages 556-559

  Adès, Lionel ^a   Chevret, Sylvie ^b   Raffoux, Emmanuel ^b   Guerci Bresler, Agnes ^c   Pigneux, Arnaud ^d   Vey, Nobert ^e   Lamy, Thierry ^f   Huguet, Francoise ^g   Vekhoff, Anne ^h   Lambert, Jean Francois ⁱ   Lioure, Bruno ^j   de Botton, Stephane ^k   Deconinck, Erick ^l   Ferrant, Augustin ^m   Thomas, Xavier ⁿ   Quesnel, Bruno ^o   Cassinat, Bruno ^b   Chomienne, Christine ^b   Dombret, Hervé ^b   Degos, Laurent ^b   Fenaux, Pierre ^a   more..

^a UNIVERSITÉ PARIS 13   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e INSTITUT PAOLI CALMETTES   (France)

^f RENNES UNIVERSITY HOSPITAL   (France)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^j UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^k INSTITUT GUSTAVE ROUSSY   (France)

^l UNIVERSITY HOSPITAL OF BESANÇON   (France)

^m DCE JM JPS) Univ H   (Belgium)

ⁿ HOSPICES CIVILS DE LYON   (France)

^o LILLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYTARABINE; DAUNORUBICIN; MERCAPTOPURINE; METHOTREXATE; RETINOIC ACID;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; EUROPE; FOLLOW UP; HUMAN; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME; TRETINOIN;

EID: 84879409297     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23451     Document Type: Article

References (20)

1. Lo-Coco F, Avvisati G, Orlando SM, et al. ATRA and arsenic trioxide (ATO) versus ATRA and Idarubicin (AIDA) for newly diagnosed, non high-risk acute promyelocytic leukemia (APL): Results of the phase III, prospective, randomized, intergroup APL0406 study by the Italian-German cooperative groups Gimema-SAL-AMLSG. ASH Ann Meet Abst 2012;120:6.
2. Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006;107:3469-3473.
3. Sanz MA, Grimwade D, Tallman MS, et al. Guidelines on the management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113:1875-1891.
4. Sanz MA, Montesinos P, Rayon C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: Further improvements in treatment outcome. Blood 2010;115:5137-5146.
5. Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: Results of the AIDA-2000 trial of the GIMEMA Group. Blood;116:3171-3179.
6. Ades L, Chevret S, Raffoux E, et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006;24:5703-5710.
7. Ades L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): A comparison of French-Belgian-Swiss and PETHEMA results. Blood 2008;111:1078-1084.
8. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999;94:1192-1200.
9. Ades L, Guerci A, Raffoux E, et al. Very long-term outcome of acute promyelocytic leukemia after treatment wtih all trans retinoic acid and chemotherapy: The European APL Group experience. Blood 2009;115:1690-1696.
10. Kaplan E, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assos 1958;53:457.
11. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. JASA 1999;94:496-509.
12. Gray R. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1998;16:1141-1154.
13. Kelaidi C, Ades L, Chevret S, et al. Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline-based chemotherapy: The European APL group experience (APL 91 and APL 93 trials). Leukemia 2006;20:905-907.
14. Ades L, Guerci A, Raffoux E, et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: The European APL Group experience. Blood 2009;115:1690-1696.
15. Sanz MA, Martin G, Lo Coco F. Choice of chemotherapy in induction, consolidation and maintenance in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003;16:433-451.
16. Iland HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and intravenous arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 2012;120:1570-1580.
17. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and over-all survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010;116:3751-3757.
18. Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2004;101:5328-5335.
19. Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood 2006;107:2627-2632.
20. Gavamzadeh A, Alimoghaddam K, Ghaffari S, et al. Treatment of acute promyelocytic leukemia with arsenic trioxyde without ATRA and/or chemotherapy. Ann Oncol 2006;17:131-134.